Skip to main content
Clinical Trials/NCT00418041
NCT00418041UnknownNot Applicable

Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study)

Hiroaki Shimokawa, MD, PhD1 site in 1 country10,000 target enrollmentStarted: October 2006Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Sponsor
Enrollment
10,000
Locations
1
Primary Endpoint
All-cause death

Study Overview

Brief Summary

Chronic Heart Failure Analysis and Registry in the Tohoku District 2 (CHART-2 Study) is a large, prospective, hospital-based cohort study to investigate the following:

  • Characteristics of patients with chronic heart failure and prognostic risks of these patients.
  • Characteristics of patients with high risk for heart failure and critical factors which predict the development of symptomatic heart failure in these patients.
  • The incidence and prognostic impact of metabolic syndrome in patients with chronic heart failure.
  • The association between metabolic syndrome and the development of symptomatic heart failure.

Detailed Description

The CHART-2 Study is a multicenter prospective observational cohort study identifying the characteristics, mortality and prognostic risks of patients with overt HF and patients without HF but who are at high risk for disease progression of cardiovascular diseases (CVD).

The purposes of the study are as follows:

  1. to elucidate characteristics of patients with overt HF and the associated prognostic risks
  2. to elucidate characteristics of patients at risk for HF and the factors associated with CVD progression
  3. to elucidate factors associated with the development of AHFS
  4. to elucidate prevalence and prognostic impact of metabolic syndrome (MetS) in patients with overt HF
  5. to elucidate the association between MetS and the development of AHFS
  6. to elucidate the prevalence and prognostic impact of malignancy in patients with CVD
  7. to elucidate the prevalence of patients needing home nursing care and the characteristics of bedridden patients with CVD.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
20 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Structural heart disease but without signs or symptoms of heart failure.
  • •Structural heart disease with prior or current symptoms of heart failure.
  • •Refractory heart failure requiring specialized interventions.
  • •Patients with prior cardiovascular surgery or percutaneous coronary intervention and those who need such interventions.

Exclusion Criteria

  • •Patients with age<20 years old.
  • •Patients who refused to participate.

Outcomes

Primary Outcomes

All-cause death

Time Frame: At the time of registration and at least once a year thereafter

Heart failure requiring admission

Time Frame: At the time of registration and at least once a year thereafter

Non-fatal stroke

Time Frame: At the time of registration and at least once a year thereafter

Non-fatal acute myocardial infarction

Time Frame: At the time of registration and at least once a year thereafter

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Hiroaki Shimokawa, MD, PhD
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Hiroaki Shimokawa, MD, PhD

Department of Cardiovascular Medicine

Tohoku University

Study Sites (1)

Loading locations...

Similar Trials